Table 2.

Treatment exposure in all patients and patients who received maintenance

	All patients (N = 85)	Patients who received ixazomib maintenance (N = 10)
Median cycles of ixazomib received, n (range)	6 (1–20)	14 (11–20)
Cycles of ixazomib received, n (%)
≥ 3	74 (87.1)	10 (100.0)
≥ 6	51 (60.0)	10 (100.0)
≥ 9	24 (28.2)	10 (100.0)
Number of patients with dose reduction, n (%)	3 (3.6)	0
Patients proceeded to SCT	6 (7.1)	0
Patients remaining on treatment, n (%)	48 (56.5)	9 (90.0)
Reason for ending treatment, n (%)
Adverse event	13 (15.3)	0
Disease progression	6 (7.1)	1 (10.0)
Another a	18 (21.1)	0

SCT, stem cell transplantation

^aReasons included proceeding to SCT, alternate therapy, poor compliance, loss of drug accessibility during the pandemic of COVID-19 and economic concerns